Payment overview · 2025
General Payments
$930.94
14 reported records · 5 companies
Healthcare provider profile · identity verified
Ronald Wayne Johnson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ARDEN, NC · NPI 1134128028
Verified facts
What the public records show
CMS Open Payments records show Ronald Wayne Johnson, M.D. received $930.94 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $360.05 | 38.7% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $292.52 | 31.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $187.88 | 20.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.58 | 7.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.91 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $930.94 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $282.81 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $235.48 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.57 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $70.58 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.76 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $9.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 521 | 148 |
| Lisinopril | Lisinopril | 269 | 76 |
| Tramadol Hcl | Tramadol Hcl | 261 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 60 |
| Omeprazole | Omeprazole | 194 | 57 |
| Lorazepam | Lorazepam | 178 | 28 |
| Metformin Hcl Er | Metformin Hcl | 178 | 48 |
| Alprazolam | Alprazolam | 166 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 45 |
| Gabapentin | Gabapentin | 152 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 143 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 139 | 40 |
| Ibandronate Sodium | Ibandronate Sodium | 132 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 37 |
| Furosemide | Furosemide | 130 | 48 |
| Losartan Potassium | Losartan Potassium | 119 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 39 |
| Simvastatin | Simvastatin | 113 | 34 |
| Meloxicam | Meloxicam | 111 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 98 | 29 |
| Celecoxib | Celecoxib | 97 | 37 |
| Eliquis | Apixaban | 95 | 25 |
| Trazodone Hcl | Trazodone Hcl | 95 | 30 |
| Metformin Hcl | Metformin Hcl | 90 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 26 |
| Montelukast Sodium | Montelukast Sodium | 85 | 28 |
| Potassium Chloride | Potassium Chloride | 83 | 25 |
| Allopurinol | Allopurinol | 81 | 20 |
| Prednisone | Prednisone | 79 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 18 |
| Atenolol | Atenolol | 75 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 17 |
| Bupropion Xl | Bupropion Hcl | 71 | 23 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Pregabalin | Pregabalin | 69 | 15 |
| Temazepam | Temazepam | 68 | suppressed |
| Clonazepam | Clonazepam | 66 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 18 |
| Carvedilol | Carvedilol | 64 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 23 |
| Ondansetron Odt | Ondansetron | 63 | 34 |
| Famotidine | Famotidine | 61 | 19 |
| Irbesartan | Irbesartan | 55 | 18 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Jardiance | Empagliflozin | 51 | 11 |
| Azithromycin | Azithromycin | 50 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 17 |
| Ezetimibe | Ezetimibe | 49 | 18 |
| Finasteride | Finasteride | 49 | 15 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Ozempic | Semaglutide | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Ramipril | Ramipril | 43 | suppressed |
| Estradiol | Estradiol | 40 | 12 |
| Glimepiride | Glimepiride | 40 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 15 |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 11 |
| Acebutolol Hcl | Acebutolol Hcl | 34 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 21 |
| Spironolactone | Spironolactone | 32 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 13 |
| Lovastatin | Lovastatin | 29 | 11 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 12 |
| Topiramate | Topiramate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | 11 |
| Baclofen | Baclofen | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $930.94 · 14 records | Amgen Inc. | BREZTRI, EVENITY, NEXIUM, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, The Cologuard Plus Collection Kit, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error